Overall Survival
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Arun A Azad, Daniel P Petrylak, Taro Iguchi, Neal D Shore, Arnauld Villers, Francisco Gomez-Veiga, Antonio Alcaraz, Boris Alekseev, Russell Z Szmulewitz, Jeffrey Holzbeierlein, Brad Rosbrook, Jie Ma, Fabian Zohren, Nader N El-Chaar, Gabriel P Haas, Arnulf Stenzl, Andrew J Armstrong
JAMA Netw Open 8(5) e258751
IMPORTANCE: In men with metastatic hormone-sensitive prostate cancer (mHSPC), prostate-specific antigen (PSA) decline after treatment has been associated with improved survival. However, the data on PSA decline are limited in men with mHSPC after treatment with enzalutamide plus androgen deprivation therapy (ADT). OBJECTIVE: To evaluate the association of enzalutamide plus ADT in men with mHSPC by PSA level at study enrollment in individuals with prior ADT and by degree of PSA reduction with clinical end points. DESIGN, SETTING, AND PARTICIPANTS: This post hoc secondary analysis was performed on data collected from the ARCHES multinational, double-blind, phase 3 randomized clinical trial. In the ARCHES trial, men with mHSPC were randomized between March 21, 2016, and January 12, 2018. Analyses were performed in October 2018 (median follow-up, 14.4 months; IQR, 11.2-17.7 months) and May 2021 (median follow-up, 44.6 months; IQR, 41.3-48.6 months). INTERVENTION: Patients were randomized 1:1 to enzalutamide (160 mg/d) plus ADT or placebo plus ADT. ADT received for 3 to 6 months before study enrollment was permitted. MAIN OUTCOMES AND MEASURES: Radiographic progression-free survival (rPFS) and overall survival (OS) were correlated post hoc with PSA level at enrollment in patients with prior ADT and additionally with PSA decline at 6 months or undetectable PSA (<0.2 ng/mL) during study treatment. RESULTS: A total of 1150 men (median age, 70 years; range, 46-92 years) were enrolled. Improvement in clinical outcomes such as rPFS was seen with enzalutamide plus ADT in men with PSA levels at enrollment of 0.2 to 4 ng/mL and above 4 ng/mL. Hazard ratios (HRs) for improved rPFS in men with PSA levels up to 0.2 ng/mL, above 0.2 to 4 ng/mL, and above 4 ng/mL were 0.59 (95% CI, 0.27-1.30), 0.32 (95% CI, 0.20-0.50), and 0.44 (95% CI, 0.32-0.62), respectively. Patients treated with enzalutamide plus ADT who achieved undetectable PSA had an 86.0% reduced risk of radiographic disease progression (HR, 0.14 [95% CI, 0.09-0.23]; P < .001) and a 76.0% reduced risk of death (HR, 0.24 [95% CI, 0.17-0.34]; P < .001). CONCLUSIONS AND RELEVANCE: In this secondary analysis of a randomized clinical trial, patients with mHSPC treated with enzalutamide plus ADT vs placebo plus ADT had improved clinical outcomes regardless of PSA level at enrollment. Undetectable PSA was associated with improved clinical outcomes with enzalutamide treatment. Future studies are required to further characterize the clinical utility of further treatment intensification among men with mHSPC for whom ADT plus enzalutamide fails to achieve undetectable PSA. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02677896.
4 个 Figure · 8 个 KM 面板
Figure 2.. Kaplan-Meier Plots of Overall Survival (OS) Adjusted for Crossover by Prostate-Specific Antigen (PSA) Categories (≤0.2, >0.2-4, or >4 ng/mL) at Study Enrollment Analysis was conducted in intention-to-treat patients with prior androgen deprivation therapy (ADT) use. The data cutoff date was May 28, 2021. Events were death from any cause. Time from randomization to death from any cause. For patients still alive at the date of the analysis cutoff point, OS was censored on the last date the patient was known to be alive. For the overall population, the log-rank test was stratified by treatment group, volume of disease, and prior docetaxel use. Within each treatment group, the log-rank test was stratified by volume of disease and prior docetaxel use. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.
Figure 2 · Panel A
Panel A 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel B
Panel B 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 2 · Panel C
Panel C 是同一 Figure 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3.. Kaplan-Meier Plots of Radiographic Progression-Free Survival (rPFS) and Overall Survival (OS) by Prostate-Specific Antigen (PSA) Decline (to < 0.2, 0.2-4, or >4 ng/mL) at 6 Months Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline and available 6-month PSA values. The data cutoff date was May 28, 2021. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.
Figure 3 · Panel A
Panel A 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 3 · Panel B
Panel B 是同一 Figure 3 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 4.. Kaplan-Meier Plot of Time to Achieve Undetectable Prostate-Specific Antigen (PSA) by Treatment Group Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline. The data cutoff date was October 14, 2018. Note that the additional patient in the placebo plus ADT group was included at the later data cutoff date of May 28, 2021. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.
Figure 4 · Panel Figure_4
Panel Figure_4 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Figure 5.. Kaplan-Meier Plots of Radiographic Progression-Free Survival (rPFS) and Overall Survival (OS) by Prostate-Specific Antigen (PSA) Decline to Undetectable ( < 0.2 ng/mL) at Any Time During the Treatment Period Analysis was conducted in intention-to-treat patients treated with enzalutamide plus androgen deprivation therapy (ADT) with detectable PSA at baseline. Events were death from any cause. Time from randomization to death from any cause. For patients still alive at the date of the analysis cutoff point, OS was censored on the last date the patient was known to be alive. The data cutoff dates for OS and rPFS were May 28, 2021, and October 14, 2018, respectively. To convert PSA to micrograms per liter, multiply by 1.0. HR indicates hazard ratio.
这些图片未产生 KM 曲线结果,不在主页面重复展示。